Phase II study of Vyvanse (Shire) for Binge Eating Disorder

A study to evaluate the safety and efficacy of Vyvanse(lisdexamfetamine dimesylate) Capsules 30, 50 or 70 mg compared to placebo in adults with Binge Eating Disorder at Week 11 as measured by the number of binge days per week as assessed by clinical interview based on patient diary. A binge day was defined as a day during which at least one binge episode occurred. The primary study end point was the change from baseline to Week 11 in log transformed (number of binge days per week + 1). Vyvanse 50 mg and 70 mg were statistically superior to placebo on the primary end point. Vyvanse 30 mg was not statistically superior to placebo on the primary end point, clarifying the dose range for future trials in this patient population.